


### **Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application.

**Listing of Claims:**

### 1. (Original) A compound of formula (I)



wherein:

T and W independently represent CR<sup>1</sup> or N; and when more than one R<sup>1</sup> group is present, each may be selected independently;

X and R<sup>1</sup> independently represent H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to Claim 1 wherein Y represents CN or halogen.

3. (Currently Amended) A compound according to Claim 1 [[or 2]] wherein X and R<sup>1</sup> independently represent H, halogen or CF<sub>3</sub>.

4. (Original) A compound of formula (I), according to Claim 1, which is:

2-[[ $(1R,3S)$ -3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-3-pyridinecarbonitrile;

2-[[ $(1R,3S)$ -3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chloro-benzonitrile;

$(2S,4R)$ -2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol;

2-[[ $(1R,3S)$ -3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile;

2-[[ $(1R,3S)$ -3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-benzonitrile;

or a pharmaceutically acceptable salt thereof.

5. (Cancelled)

6. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) according to ~~any one of Claims 1 to 4~~ Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

7-12. (Cancelled)

13. (Currently Amended) The use of A method for the treatment or prophylaxis of pain comprising administering a compound of formula (I) as defined in any one of Claims 1 to 4 Claim 1, or a pharmaceutically acceptable salt thereof, ~~in the manufacture of a medicament, for the treatment or prophylaxis of pain.~~

14. (Currently Amended) The use of A method for the treatment or prophylaxis of an inflammatory disease comprising administering a compound of formula (I) as defined in any one of Claims 1 to 4 Claim 1, or a pharmaceutically acceptable salt thereof, ~~in combination with and a COX-2 inhibitor, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.~~


15. (Currently Amended) A method of treating, or reducing the risk of, a human disease or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 4 Claim 1, or a pharmaceutically acceptable salt thereof, ~~to a person suffering from, or at increased risk of, such diseases or conditions.~~

16. (Currently amended) A method of treatment according to Claim 15 in which it is predominantly inducible nitric oxide synthase that is inhibited.


17. (Currently Amended) A method of treating, or reducing the risk of, an inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering ~~to the person~~ a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 4 Claim 1, or a pharmaceutically acceptable salt thereof.

18. (Currently Amended) A process for the preparation of a compound of formula (I), as defined in any one of Claims 1 to 4 Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, wherein the process comprises:

(a) reaction of a compound of formula (II)




wherein T, X, Y and W are as defined in Claim 1 and L<sup>1</sup> represents a leaving group, with a compound of formula (III)



(III)


or

(b) reaction of a compound of formula (IV)



(IV)

wherein T, W, X and Y are as defined in Claim 1,  
with a compound of formula (V)



(V)

wherein L<sup>2</sup> is a leaving group;

~~and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof, or converting one compound of formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.~~

19. (New) A process as defined in Claim 18, further comprising:  
converting the resultant compound of formula (I) into a pharmaceutically acceptable salt thereof; converting the resultant compound of formula (I) into another compound of formula (I); or  
converting the resultant compound of formula (I) into an optical isomer thereof.
20. (New) A compound according to Claim 2, wherein X and R<sup>1</sup> independently represent H, halogen or CF<sub>3</sub>.
21. (New) The method as claimed in Claim 17, wherein the inflammatory disease is inflammatory bowel disease.
22. (New) The method as claimed in Claim 17, wherein the inflammatory disease is rheumatoid arthritis.
23. (New) The method as claimed in Claim 17, wherein the inflammatory disease is osteoarthritis.